---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-058701"
form_type: "8-K"
ticker: "STRO"
cik: "0001382101"
company_name: "SUTRO BIOPHARMA, INC."
filed_at: "2024-05-13T23:59:59+00:00"
generated_at: "2026-06-02T02:02:38.500853+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Sutro Biopharma Q1 2024: Revenue $13.0M, Cash $267.6M; IND cleared for NSCLC trial

## Summary
- Q1 2024 revenue of $13.0M (vs $12.7M YoY); total operating expenses $69.6M ($56.9M R&D, $12.7M G&A).
- Cash and investments $267.6M plus $45.6M in Vaxcyte shares; April added $75M from Ipsen licensing and $75M equity offering.
- IND cleared for luvelta in NSCLC; Phase 2 expected to start H2 2024, initial data H1 2025.
- REFRαME-O1 registration trial for PROC now enrolling; pediatric AML trial expected to begin H2 2024.
- STRO-003 licensed to Ipsen; Sutro eligible for up to $899M in milestones plus tiered royalties.

## SEC filing metadata
- accession: 0000950170-24-058701
- form_type: 8-K
- ticker: STRO
- cik: 0001382101
- company_name: SUTRO BIOPHARMA, INC.
- filed_at: 2024-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1382101/000095017024058701/0000950170-24-058701-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1382101/000095017024058701/stro-20240513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-058701
- JSON: https://secwatch.observer/filing/0000950170-24-058701.json
- Plain text: https://secwatch.observer/filing/0000950170-24-058701.txt

## Key facts
- Earnings Releases
  SUTRO BIOPHARMA, INC. reported the quarter ended March 31, 2024 results: revenue $13.0 million, net income $267.6 million.
  - Period: the quarter ended March 31, 2024
  - Revenue: $13.0 million
  - Net income: $267.6 million
  - Result: reported results
  source text: stock on the last trading day of each reporting period, with any non-operating, unrealized gains and losses recorded in Sutro’s statements of operations. Revenue Revenue was $13.0 million for the quarter ended March 31, 2024, as compared to $12.7 million for the same period in 2023, with the 2024 amount related principally to the Astellas collaboration, and the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1382101/000095017024058701/0000950170-24-058701-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.